Clinical trial
REGISTRY OF COMPLETE RESPONSES TO SUNITINIB IN SPANISH PATIENTS WITH METASTATIC RENAL CELL CARCINOMA (ATILA STUDY)
NCT03916458 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- REGISTRY OF COMPLETE RESPONSES TO SUNITINIB IN SPANISH PATIENTS WITH METASTATIC RENAL CELL CARCINOMA (ATILA STUDY)
- Lead sponsor
- Pfizer
- Phase
- Observational
- Overall status
- Completed
- Start date
- December 17, 2019
- Completion date
- November 3, 2020
- Enrollment
- 62 (actual)
- Sites
- 31
Conditions
As the registry lists them; a condition with its own page is linked.